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Low Molecular Weight Heparin (Enoxaparin) versus Dextran in the
Prevention of Early Occlusion Following Arterial Bypass Surgery
Distal to the Groin
K. Logason and D. Bergqvist, on behalf of the Study Group on Antithrombotic Prophylaxis of
Femorodistal Bypass Surgery∗ (within Swedvasc†)
Department of Surgery, University Hospital, 5-751 85 Uppsala, Sweden
Aim: to compare the effect of perioperative dextran and low molecular weight heparin on early graft patency after
femorodistal bypass surgery.
Design: prospective randomised multicentre study.
Patients and methods: three hundred and fourteen patients were randomised to dextran 70 or the low molecular weight
heparin enoxaparin during and after femorodistal bypass surgery. Patency was evaluated at days 1, 5–7, 30 and 90.
Results: there was no difference in patency at any time point between the two regimens, the crude 90 days patency being
88 and 83%, respectively. There were significantly more patients with heart failure in the dextran group (12.8 vs. 0.7%),
with other side effects being equally distributed.
Conclusion: dextran 70 and the low molecular weight heparin enoxaparin have the same effect on 90 days femorodistal
graft patency, but care must be taken using the dextran to patients with a potential heart insufficiency.
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Introduction (enoxaparin) on early patency following femorodistal
bypass surgery.
One main problem in vascular surgery is the tendency
of vascular grafts to occlude with time, especially those
in arteries with high resistance.1 A number of measures Patients and Methods
have been tried to reduce the risk, either decreasing
thrombogenicity (heparin, antiplatelet drugs, oral anti- During a 2-year period patients scheduled to undergo
coagulants)2–6 or increasing flow (A-V fistulas,7 sym- bypass from the groin to a distal site were considered
pathetic block), but none has been entirely successful. for inclusion in this study. Exclusion criteria were: lack
Dextran possesses both flow-promoting and anti- of informed consent, hypersensitivity to dextran or
thrombotic properties8,9 and dextran 40 has been heparin, bleeding disorders, continuous therapy with
shown to be effective in preventing early postoperative anticoagulants for other reasons, manifest heart failure,
occlusion following arterial bypass surgery.10 While serum creatinine >200 mol/l and pregnancy. Separate
low molecular weight heparins (LMWH) have theor- randomisation was made at each participating centre.
etical advantage in having both anti-thrombotic and Sequentially numbered sealed envelopes were opened
antiproliferative properties,11 the effect in vascular sur- when the decision had been made to include the
gery is poorly documented. patient. The group (in the envelope) had been gen-
The aim of this study was to compare the effect erated by computer random lists. Three hundred and
of dextran 70 with a low molecular weight heparin fourteen patients from 16 centres were randomised.
For practical reasons the study was not blind, but the
surgeon assessing patency was blinded to the group.
∗ Scientific committee: David Bergqvist, Bengt Lindblad, Stefan Ma- Patients randomised to the dextran 70 group re-
thiasson, Thomas Troe¨ng. ceived dextran 70 (Macrodex, Pharmalink, Sweden) in
† Steering committee: David Bergqvist, Thomas Troe¨ng, Johan Elf- a total dose of 2500 ml according to the followingstro¨m, Bengt Hedberg, K.-G. Ljungstro¨m, Lars Norgren, Per O¨r-
tenwall. regimen: 500 ml beginning at the time of anaesthesia
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Table 1. Exclusion after randomisation (number of patients).induction, 500 ml postoperatively following the first
infusion, and 500 ml beginning on the morning of Dextran Enoxaparin Total
postoperative days 1, 2 and 3. Before the first infusion
Anticoagulation before or after 5 5 10heparin dextran 1 (10 ml Promiten) was injected. At
surgerycross-clamping heparin 5000 IU were given i.v. A dex- Improper randomisation 2 3 5
Planned operation not 3 2 5tran dose above 5 ml/kg bw/day was accepted as
performedcorrect treatment. The surgeons in care of the patients
Incorrect treatment 1 4 5were informed to reduce the infusion rate in patients Creatinine >200 mol/l 1 2 3
with potential risk for heart failure. Total 12 16 28
Patients randomised to the LMWH group received
enoxaparin (Klexane, Aventis, Sweden) 40 mg s.c. on
Table 2. Risk factors at baseline.∗the day before surgery and the same dose was repeated
s.c. every evening for 7 days. At crossclamping 20 mg Dextran Enoxaparin
enoxaparin were given i.v.
Diabetes 47/145 49/132The groups were compared for patency at day 1,
Hypertension 66/144 45/133days 5–7, day 30 and at 3 months postoperatively. Cardiac 61/145 61/133
Pulmonary 14/141 11/132Pulse palpation (graft pulse and ankle and popliteal
Smoking 63/129 58/125pulse), ankle/brachial pressure index (a decrease of
Mean age, years±SD 74±9.4 73±8.8>0.15) and clinical judgement were used to determine
∗Risk factors are registered in Swedvasc as present, absent orpatency. In every case of uncertainty duplex scanning
unknown, explaining the apparently missing cases in Table 2.or angiography was used to determine whether or not
the graft was patent. Patency was assessed blindly.
Table 3. Indications for bypass surgery.The treatment groups were compared with regard to
blood loss during surgery, in drains after surgery and Dextran Enoxaparin
(n=149) (n=137)units of red cells transfused during and after surgery.
Haemoglobin, platelet count, serum creatinine and Acute ischaemia 2 (1%) 4 (3%)
APTT were measured preoperatively and at days 5–7 Intermittent claudication 23 (15%) 24 (18%)
Rest pain 50 (34%) 36 (26%)postoperatively. Complications in the form of allergy,
Ulcer or gangrene 74 (50%) 73 (53%)haemorrhage, myocardial infarction, heart failure and
death were registered as was the use of platelet in-
Table 4. Operations performed, with regard to the distal ana-hibitors. Additional information on the type of oper-
stomosis.ation, indication and risk factors was taken from the
Swedish vascular registry (Swedvasc). For the specific Dextran Enoxaparin
(n=149) (n=137)information in this study a protocol was added to the
standard Swedvasc protocol. The study was approved
Femoropopliteal bypass 44 (30%) 49 (36%)
by the regional ethics committees, to which the various above knee
Femoropopliteal bypass 61 (41%) 47 (34%)hospitals belonged. Chi-squared test, Wilcoxon rank
below kneesum test and log rank test were used where ap-
Femorocrural bypass 42 (28%) 41 (30%)
propriate. p<0.05 was considered significant. The
sample size was calculated to show a difference in
Table 5. Patency at 3 months for vein grafts vs. prosthesis andpatency of more than 10% with a p<0.05 and a power
composite grafts.of 80%.
Dextran Enoxaparin
Vein grafts 66/73 (90%) 54/68 (80%)Results Prosthesis or composite graft 56/65 (86%) 55/63 (87%)
Of the 314 randomised patients, 28 were excluded for
various reasons (Table 1). This means that 149 patients 137 in the enoxaparin group (54% vs. 50%). In the
remaining patients the graft was either a syntheticin the dextran group and 137 in the enoxaparin group
were further analysed. Comparison with regard to risk vascular prosthesis or a composite graft. The patency
rate at 3 months was comparable between vein graftsfactors, indication for operation and type of operation
(Tables 2, 3 and 4) showed no significant differences and other grafts and also when comparing the groups
for either graft type (Table 5). The use of plateletbetween the treatment groups. Vein graft was used in
80 of 149 patients in the dextran group and 69 of inhibitors (mainly aspirin) was similar in the groups
Eur J Vasc Endovasc Surg Vol 21, March 2001
Enoxaparin vs. Dextran in Distal Bypass Surgery 263
Table 6. Laboratory data at baseline and 5–7 days postoperatively. Discussion
Dextran Enoxaparin
In spite of intensive research, the problem of vascular
Preop. Days 5–7 Preop. Days 5–7 bypass graft occlusion with time is still unresolved. In
particular, grafts to distal, high resistance arteriesHaemoglobin 132±18 109±13 131±16 114±14
Platelet count 286±126 262±100 308±131 316±137 have alarmingly high occlusion rates, more so if a syn-
Creatinine 96±29 102±48 97±30 98±36 thetic vascular prosthesis has to be chosen as a graft
APTT 28.0±4.3 30.6±6.5 28.9±5.6 28.7±4.4 material.12
Apart from technical errors and later progress of
Table 7. Patency at day 1, days 5–7, day 30 and at 3 months.
atherosclerosis in inflow and outflow vessels, common
Dextran Enoxaparin reasons for graft occlusion are early thrombosis be-
cause of high thrombogenicity of the reconstruction
Patent grafts/Patients Patent grafts/Patients
and later pseudointimal hyperplasia, which mainlyalive alive
occurs at the anastomosis of a synthetic prosthesis but
Patency day 1 147/149 (99%) 132/137 (96%) may occur anywhere along autologous vein grafts.13
Patency days 143/147 (97%) 125/136 (92%)
The relation between thrombus formation and the5–7
Patency day 30 137/144 (95%) 118/133 (89%) later development of pseudointimal hyperplasia is not
Patency at 3 122/138 (88%) 109/131 (83%) clear. However, it is logical to try to reduce the risk
months
of early occlusion by reducing the thrombotic potential
None of these results reached statistical significance. or later stenosis or occlusion by reducing pseudo-
p>0.05 Chi square, Log Rank test 0.25>p>0.1. intimal hyperplasia. Measures reducing the thrombotic
potential by increasing flow such as A-V fistula7 orTable 8. Complications (number of patients).
sympathetic block are controversial and still under
Dextran Enoxaparin p-value evaluation. Acetylsalicylic acid has been shown to
moderately reduce the risk of occlusion in cases whereAllergic reaction 0 0
Bleeding 9 3 NS a vascular prosthesis has to be used.2,3 It has not been
Myocardial infarction 4 5 NS effective when a vein graft can be used4 and the effectHeart failure 19 (12.8%) 1 (0.7%) <0.001
on pseudointimal hyperplasia is doubtful. Ticlopidine,Death 5 4 NS
another antiplatelet drug, has been shown to reduce
and had no significant effect on patency over the the risk for occlusion after vein bypass surgery.14 Oral
3 months period. Comparison of laboratory data at anticoagulants have been effective to increase patency
baseline and at days 5–7 showed no significant dif- in vein grafts5,6 although other studies have not been
ferences between the groups (Table 6). able to confirm this.15 Heparin is the traditionally used
There were no significant differences between the substance for intraoperative anticoagulation, although
groups in patency at day 1, days 5–7, day 30 or at 3 the documentation of its effect is scarce.16 Although
months (Table 7). The frequency of bleeding com- these agents can be successful in some situations the
plications did not differ. The amount of blood loss occlusion rate is still alarmingly high, indicating room
perioperatively was 370±277 ml in the dextran group for improvement. The substances under investigation
vs. 363±343 ml in the enoxaparin group. The patients in this study should reduce the risk for occlusion by
in the dextran group appeared to receive a higher two mechanisms. Dextran has both flow-promoting
volume of blood transfusion (278±493 ml) than and antithrombotic properties,8,9 and has been shown
patients in the enoxaparin group (154±330 ml), but to be effective in preventing early postoperative oc-
the difference was not statistically significant. The clusions following infrainguinal bypass surgery.10
different incidence of heart failure (12.8% vs. 0.7%, This study included mostly difficult distal bypasses,
p<0.001) was significant. The patients in the dextran many with synthetic grafts. Including only patients
group with cardiac complications (myocardial in- with a poor runoff could have provoked a difference.
farction or heart failure) were older (mean age 78) and A more recent study of dextran 40 on vein graft
had more cardiac risk factors (12 out of 14 where patency did not show any effect.17 Except for the higher
information was available) than other patients in the immediate volume effect there are no data to support
dextran group. The dextran patients with cardiac com- that dextran 70 should be inferior to dextran 40. Be-
plications also received larger transfusion volumes of cause of the difference in cost and the dominating use
556±733 ml, in spite of bleeding only 394±266 ml. in the clinical situation, dextran 70 was used in this
The complications are listed in Table 8. There was no study. LMWH has both antiproliferative18 and anti-
thrombotic19 effects. Clinical studies have shown themdifference in mortality between the groups.
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